Showing results (311-320 of 365) with videos related to

Sort By:
Pageof 37
Immunotargets and Therapy|November 28, 2024
Novel Insights into Causal Effects of Lipid and Lipid-Lowering Targets with Autoimmune Thyroid Disease: A Mendelian Randomization StudyChang Su, Juan Tian, Xueqing He, et al.
Immunotargets and Therapy|March 17, 2025
Development and Characterization of 4A7: A High-Affinity Monoclonal Antibody Targeting Claudin18.2Yahui Wu, Juan Tian, Yangyihua Zhou, et al.
Immunotargets and Therapy|October 21, 2024
Harnessing Variability Signatures and Biological Noise May Enhance Immunotherapies' Efficacy and Act as Novel Biomarkers for Diagnosing and Monitoring Immune-Associated DisordersTal Sigawi, Adir Israeli, Yaron Ilan
Immunotargets and Therapy|October 4, 2024
EPS T14 from Bacillus licheniformis Prevents Infection of Human Nasal Epithelial Cells by Respiratory VirusesGaetana Pezzino, Alessia Calabrò, Fabiana Drommi, et al.
Immunotargets and Therapy|September 11, 2024
Clinical Significance and Molecular Annotation for PD-L1 Negative Advanced Non-Small Cell Lung Cancer with Sensitivity to Responsive to Dual PD-1/CTLA-4 BlockadeLi Wang, Li Liu, Jing Zhao, et al.
Immunotargets and Therapy|July 29, 2024
Optimal Assessment, Treatment, and Monitoring of Adults with Eosinophilic Esophagitis: Strategies to Improve OutcomesPierfrancesco Visaggi, Matteo Ghisa, Edoardo Vespa, et al.
Immunotargets and Therapy|July 9, 2024
A Case Report of Pathologically Complete Response of a Huge Lymph Node Metastasis of Colorectal Cancer After Treatment with Intratumoral Oncolytic Virus H101 and CapecitabineYaqin Wang, Tianxiao Wang, Yuewei Zhang
Immunotargets and Therapy|July 8, 2024
Mycobacterium tuberculosis Biofilms: Immune Responses, Role in TB Pathology, and Potential TreatmentMuluneh Assefa, Getu Girmay
Immunotargets and Therapy|June 17, 2024
Mendelian Randomization Analysis of Circulating Cytokines and Risk of Autoimmune Neuroinflammatory DiseasesSha-Sha Tao, Fan Cao, Ruo-Di Zhang, et al.
Immunotargets and Therapy|June 24, 2024
Survival Benefit of Synchronous Lenvatinib Combined PD-1 Inhibitors for Advanced Hepatocellular Carcinoma Beyond OligometastasisKaiwu Xu, Cailing Xiang, Zhige Yu, et al.
Pageof 37